• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 7
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue7

Clinical-Neurophysiologic, Immunological Features And Diagnosis Of Antifosfolipid Syndrome By Cerebra-Vascular Disorders At Background Systemic Diseases Of Connective Tissue

    Oybek Bustanov Nargiza Nasirdinova Oydin Kuchkarova Odinahon Kuchkarova

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 5768-5775

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Antiphospholipid Syndrome (AFS) is one of the current multidisciplinary problems of modern medicine and is being investigated as a unique example of autoimmune thrombotic vasculopathy. This syndrome was first described in the context of Systemic lupus erythematosus (TSA) and was referred to as anticardiolipin syndrome, later renamed antiphospholipid syndrome (AFS) by the same authors. There is an immunological predisposition to increased synthesis of antiphospholipid antibodies (AFL) and most of them have been detected in relatives of patients with AFS.
The prevalence of AFS in the population is still unknown. It is possible that the synthesis of antiphospholipid antibodies (AFL) may be normal, but often low levels of antibodies are observed in the blood of a healthy person. According to various data, the rate of antibody cardiolipin (ACL) in the population varies from 0 to 14%, averaging 2-4%, with high titers detected in about 0.2% of donors.1 In Uzbekistan, systemic connective tissue is found in several people per year. The disease develops antibodies to the interaction with phospholipids - components of the cell membrane.
Keywords:
    AFS(Antiphospholipid Syndrome) UTTKDG systemic lupus erythematosus (TQB) systemic scleroderma (TSD) nervous system normal activity of beta-2-glycoprotein (B2GPI)
  • PDF (257 K)
  • XML
(2021). Clinical-Neurophysiologic, Immunological Features And Diagnosis Of Antifosfolipid Syndrome By Cerebra-Vascular Disorders At Background Systemic Diseases Of Connective Tissue. European Journal of Molecular & Clinical Medicine, 7(7), 5768-5775.
Oybek Bustanov; Nargiza Nasirdinova; Oydin Kuchkarova; Odinahon Kuchkarova. "Clinical-Neurophysiologic, Immunological Features And Diagnosis Of Antifosfolipid Syndrome By Cerebra-Vascular Disorders At Background Systemic Diseases Of Connective Tissue". European Journal of Molecular & Clinical Medicine, 7, 7, 2021, 5768-5775.
(2021). 'Clinical-Neurophysiologic, Immunological Features And Diagnosis Of Antifosfolipid Syndrome By Cerebra-Vascular Disorders At Background Systemic Diseases Of Connective Tissue', European Journal of Molecular & Clinical Medicine, 7(7), pp. 5768-5775.
Clinical-Neurophysiologic, Immunological Features And Diagnosis Of Antifosfolipid Syndrome By Cerebra-Vascular Disorders At Background Systemic Diseases Of Connective Tissue. European Journal of Molecular & Clinical Medicine, 2021; 7(7): 5768-5775.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 15
  • PDF Download: 7
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  info@ejmcm.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

Editorial Team:  editor@ejmcm.com

For Special Issue Proposal : chiefeditor.ejmcm@gmail.com / info@ejmcm.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus